Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec /insulin aspart

First Posted Date: 2018-01-31

Last Posted Date: 2021-11-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 768

Registration Number: NCT03416855

Locations: 🇰🇷
Novo Nordisk Investigational Site, Ulsan, Korea, Republic of

A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: Faster aspart
Drug: Insulin aspart (NovoRapid®)

First Posted Date: 2018-01-23

Last Posted Date: 2019-06-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT03407599

Locations: 🇩🇪
Novo Nordisk Investigational Site, Hannover, Germany

Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: Insulin degludec
Drug: Insulin Aspart
Drug: Insulin detemir

First Posted Date: 2017-12-19

Last Posted Date: 2023-01-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 225

Registration Number: NCT03377699

Locations: 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom

A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: BIAsp 30

First Posted Date: 2017-12-15

Last Posted Date: 2018-08-31

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 516

Registration Number: NCT03374774

Locations: 🇮🇳
Novo Nordisk Investigational Site, Thriruvananthapuram, India

A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver

Phase 1

Completed

Conditions: Hepatobiliary Disorders
Non-alcoholic Fatty Liver Disease

Interventions: Drug: Placebo
Drug: Semaglutide

First Posted Date: 2017-11-29

Last Posted Date: 2021-11-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 67

Registration Number: NCT03357380

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: NNC9204-1177 A 1.0 mg/mL
Drug: PLACEBO

First Posted Date: 2017-10-12

Last Posted Date: 2021-12-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 99

Registration Number: NCT03308721

Locations: 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States

A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec/liraglutide
Drug: insulin degludec
Drug: liraglutide

First Posted Date: 2017-09-25

Last Posted Date: 2019-11-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT03292185

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, Beijing, China

A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: Semaglutide 1.0 mg
Drug: Semaglutide 0.5 mg
Drug: Placebo (semaglutide 1.0 mg)
Drug: Placebo (semaglutide 0.5 mg)

First Posted Date: 2017-09-20

Last Posted Date: 2021-02-15

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 36

Registration Number: NCT03288740

Locations: 🇨🇳
Novo Nordisk Investigational Site, Beijing, China

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart
Drug: Insulin aspart
Drug: Insulin degludec
Drug: Metformin

First Posted Date: 2017-08-31

Last Posted Date: 2022-01-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1264

Registration Number: NCT03268005

Locations: 🇺🇦
Novo Nordisk Investigational Site, Vinnytsia, Ukraine

Awareness, Care and Treatment in Obesity Management

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Other: No treatment given

First Posted Date: 2017-08-01

Last Posted Date: 2019-07-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 2545

Registration Number: NCT03235102

Locations: 🇨🇦
Novo Nordisk Investigational Site, Edmonton, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy